Trial results

CagriSema results: REDEFINE 1

Last checked: November 2, 2026. Educational only, not medical advice. PeptideX is not affiliated with any drug manufacturer.

Last checked Nov 2, 2026

What were CagriSema's results?

CagriSema, a combination of cagrilintide and semaglutide from Novo Nordisk, is investigational and not FDA approved. In the 68-week REDEFINE 1 trial, people on CagriSema lost an average of 20.4% of body weight, compared with 3.0% on placebo, counting everyone assigned to treatment whether or not they kept taking it. Novo Nordisk submitted CagriSema to the FDA on December 18, 2025. As of November 2, 2026, the FDA hasn't made a decision; Novo Nordisk says it expects one in late 2026.

Sources: NEJM 2025, Garvey et al. (NCT05567796); Novo Nordisk. See also the CagriSema compound page.

Educational info, not medical advice. PeptideX doesn't give dosing advice. Talk to a licensed clinician.

Want to know when prices or approvals change?

We email you when the FDA approves a drug, a price changes, or a new option becomes available. Every email links the official source.

Some links on PeptideX may be partner links. If you sign up through one, we may earn a fee at no extra cost to you. It never changes what we write. How we make money.

Canonical: https://peptidex.ai/cagrisema-results